UCB and UK’s MRC Technology have entered an exclusive license agreement under which UCB will obtain rights to an undisclosed fibrosis therapy program. The program resulted from MRC’s collaboration with the University of Sheffield on the development of a novel antibody-based therapy targeting the progression of fibrosis. Additional terms were not disclosed.
MRC Technology will receive an upfront payment, clinical development milestones and royalties on future product sales. In accordance with the organization’s not-for-profit collaborative model, revenue will be shared with the University of Sheffield and will be reinvested to support other drug discovery programs.
“The program focuses on a key area of unmet medical need and we are committed to bringing fibrosis treatment to patients,” said Mark Bodmer, UCB New Medicines vice president and head of Immunology. “We are excited to be working with MRC Technology and University of Sheffield scientists to build on their work to date in generating and characterizing promising therapeutic approaches with the potential for significant patient impact.”
Michael Dalrymple, director of business development at MRC Technology, said, “We are delighted to be able to partner this program with UCB and we look forward to working together to ensure the project’s commercial success. This program has the potential to not only benefit fibrosis patients and help prevent organ failure, but also enables MRC Technology and its partners to help bring other new research to market.”
UCB, MRC Technology Enter Exclusive Fibrosis License
By Kristin Brooks
Published February 13, 2014
blog comments powered by Disqus